AHA is weighing in on drug shortages that impact patient care in response to a request by Republican leaders in the House and Senate. Rep. Cathy McMorris Rodgers, R-Wash., chair of the House Committee on Energy and Commerce, and Sen. Mike Crapo, R-Idaho, ranking member of the Senate Finance Committee, sought the information to better understand the issue. In its response, AHA described the wide range of shortages that impact patients suffering from a vast array of illnesses. AHA urged a number of actions, including strengthening the supply chain for prescription drugs, diversifying manufacturing sites and increasing end-user inventories, along with steps the Food and Drug Administration can take to further stabilize the nation’s supply of essential drugs. 

Related News Articles

Blog
The inability of many patients to obtain needed drug therapies due to either high prices or shortages has negatively affected patient outcomes.1 Nearly 30% of…
Headline
ASHP tracked a record 323 active drug shortages during the first quarter of 2024, surpassing the previous record of 320 shortages in 2014.“Some of the most…
Headline
The Department of Health and Human Services April 2 released a white paper proposing policy solutions for Congress and others to prevent drug shortages and…
Headline
In a statement submitted to the House Ways and Means Committee for a hearing Feb. 6 on chronic drug shortages, AHA recommended Congress enact legislation to…
Headline
Reps. Doris Matsui, D-Calif., and Larry Bucshon, R-Ind., Jan. 12 introduced a House version of the Mapping America’s Pharmaceutical Supply Act, legislation…
Headline
In a statement submitted to the Senate Finance Committee Dec. 5 for a hearing on drug shortages and potential health policy solutions, AHA reiterated its…